Plain-English translation of NCT07597902 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This research trial is testing whether a combination of three medications—, , and —can help reduce Long COVID symptoms in adults. Researchers want to see if this treatment is both safe and effective at improving how people feel and function. Half of participants will receive the actual medications, and half will receive placebo (inactive) pills to compare results.
Long COVID affects many people with ongoing symptoms months after their initial COVID infection, but current treatment options are limited. This trial explores whether targeting both viral persistence and inflammation with this combination approach might help people recover and regain their quality of life.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will take medications or placebo for 14 weeks in a specific schedule: you'll start with two medications together, add a third medication for 25 days while reducing one of the first two, then return to the original two medications. You'll have regular study visits where researchers will check your health through blood and urine tests and ask you how you're feeling. The study compares your health outcomes to those of other participants to understand whether this combination treatment works.
AI-generated summary from trial data · Oct 30, 2026 · Not medical advice
United States